Your browser doesn't support javascript.
loading
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy.
Cicek, Filiz; Troschke-Meurer, Sascha; Ceylan, Kiraz; Jahns, Luciana J; Zumpe, Maxi; Siebert, Nikolai; Ehlert, Karoline; Lode, Holger N.
Afiliação
  • Cicek F; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Troschke-Meurer S; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Ceylan K; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Jahns LJ; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Zumpe M; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Siebert N; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Ehlert K; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Lode HN; Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
Front Pediatr ; 8: 582820, 2020.
Article em En | MEDLINE | ID: mdl-33392114
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article